Abstract-Levels of Lp(a), an atherogenic lipoprotein that circulates in human plasma, are increased by the administration of growth hormone (GH). Many of the physiological effects of GH are mediated through insulin-like growth factor-1 (IGF-1), but ironically, IGF-1 treatment of humans is associated with a fall in plasma Lp(a) levels. To glean insight into the mechanism responsible for the GH-associated increase in plasma levels of Lp(a), we administered recombinant human GH (rhGH) to mice expressing a 370-kb human genomic fragment containing the apo(a) gene, 40 kb of 5Ј-, and 200 kb of 3Ј-flanking sequence [YAC-apo(a) transgenic mice]. The plasma levels of apo(a) and hepatic levels of apo(a) mRNA rose dramatically in the post-pubertal male mice in response to rhGH treatment. To determine whether the increase in plasma apo(a) was mediated by IGF-1, we treated castrated and noncastrated YAC-apo(a) transgenic mice with a continuous infusion of IGF-1 (100 g/d) for 2 weeks, and plasma levels of apo(a) fell by Ϸ50%. Thus the effects of rhGH and IGF-1 administration on plasma levels of apo(a) in the YAC-apo(a) transgenic mice simulate those seen in humans. The coordinate changes in apo(a) mRNA and plasma levels of apo(a) in response to rhGH and IGF-1 strongly suggest that these 2 hormones have independent effects on the transcription of the apo ( Key Words: apo(a) Ⅲ growth hormone Ⅲ insulin-like growth factor-1 L p(a) is an atherogenic plasma lipoprotein composed of a particle of LDL attached to a large glycoprotein, apo(a). 1 Plasma levels of Lp(a) vary over a 1000-fold range (from Ͻ0.1 mg/dL to Ͼ100 mg/dL), and most of the interindividual variation is due to inherited differences in the size and sequence of the apo(a) gene. 2 The rate of synthesis of Lp(a), rather than its degradation, correlates best with its plasma levels. 3 Our knowledge regarding the mechanism by which sequence variations in apo(a) affect plasma levels of Lp(a) is limited due to the relative paucity of appropriate model systems in which to study the synthesis and metabolism of apo(a). In humans, the apo(a) that circulates in plasma is synthesized in the liver, but cultured human hepatocytes synthesize only a trace amount of apo(a). 4 Thus no readily accessible human tissue is available for the analysis of hepatic apo(a) synthesis, and apo(a) is not present in the blood of any nonhuman species other than great apes or hedgehogs. 5, 6 Apo(a) transgenic mice have been available for 6 years but cannot be used to examine the regulation of apo(a) synthesis because the cDNA is under the control of the mouse metallothionein promoter. 7 In 1995 Frazer and colleagues developed an apo(a) transgenic mouse that expresses the human apo(a) gene within its own genomic context. 8 The mice contain a 270 kb human genomic fragment that includes the entire coding sequence of the apo(a) gene and at least 60 kb of 5Ј-and 3Ј-flanking sequences. The male and female transgenic mice have similar plasma levels of apo(a) (Ϸ20 mg/dL) until puberty. 9 At puberty the concentration of plasma apo(a) falls to almost undetectable levels in the male mice, an effect that can be completely reversed by castration. 8 The plasma apo(a) and hepatic apo(a) mRNA levels return to adult levels if the castrated male mice are given 5␣-dihydrotestosterone. 8 From these experiments, it was concluded that testosterone is responsible for the postpubertal decrease in plasma apo(a) levels in the transgenic mice. Treatment of female mice with estrogen also results in a decrease in plasma apo(a), although the effect is less pronounced. 9 Thus pharmacological levels of sex steroids profoundly affect the plasma levels of apo(a) in these mice.
L p(a) is an atherogenic plasma lipoprotein composed of a particle of LDL attached to a large glycoprotein, apo(a). 1 Plasma levels of Lp(a) vary over a 1000-fold range (from Ͻ0.1 mg/dL to Ͼ100 mg/dL), and most of the interindividual variation is due to inherited differences in the size and sequence of the apo(a) gene. 2 The rate of synthesis of Lp(a), rather than its degradation, correlates best with its plasma levels. 3 Our knowledge regarding the mechanism by which sequence variations in apo(a) affect plasma levels of Lp(a) is limited due to the relative paucity of appropriate model systems in which to study the synthesis and metabolism of apo(a). In humans, the apo(a) that circulates in plasma is synthesized in the liver, but cultured human hepatocytes synthesize only a trace amount of apo(a). 4 Thus no readily accessible human tissue is available for the analysis of hepatic apo(a) synthesis, and apo(a) is not present in the blood of any nonhuman species other than great apes or hedgehogs. 5, 6 Apo(a) transgenic mice have been available for 6 years but cannot be used to examine the regulation of apo(a) synthesis because the cDNA is under the control of the mouse metallothionein promoter. 7 In 1995 Frazer and colleagues developed an apo(a) transgenic mouse that expresses the human apo(a) gene within its own genomic context. 8 The mice contain a 270 kb human genomic fragment that includes the entire coding sequence of the apo(a) gene and at least 60 kb of 5Ј-and 3Ј-flanking sequences. The male and female transgenic mice have similar plasma levels of apo(a) (Ϸ20 mg/dL) until puberty. 9 At puberty the concentration of plasma apo(a) falls to almost undetectable levels in the male mice, an effect that can be completely reversed by castration. 8 The plasma apo(a) and hepatic apo(a) mRNA levels return to adult levels if the castrated male mice are given 5␣-dihydrotestosterone. 8 From these experiments, it was concluded that testosterone is responsible for the postpubertal decrease in plasma apo(a) levels in the transgenic mice. Treatment of female mice with estrogen also results in a decrease in plasma apo(a), although the effect is less pronounced. 9 Thus pharmacological levels of sex steroids profoundly affect the plasma levels of apo(a) in these mice.
We propose an alternative explanation for the low plasma apo(a) levels in postpubertal male mice expressing the human apo(a) gene. The fall in plasma levels of apo(a) may in part be an indirect rather than direct effect of testosterone on hepatic apo(a) expression. In rodents, sex steroids determine the secretion pattern of growth hormone (GH). Postpubertal male and female rats have similar mean plasma levels of GH; however in males, the pattern of secretion is pulsatile, whereas in females, it is more continuous. 10, 11 In mice, the pulse interval of GH secretion is longer in males (Ϸ2.5 hours) than in females (Ϸ1.4 hours), so the plasma level of GH remains more constant in the female mice. 12 The specific pattern of GH secretion, in turn, affects the expression levels of numerous hepatic genes by stimulating the expression of some genes and suppressing the expression of others. 13, 14 The male-specific pattern of GH secretion may contribute to the fall in peripubertal plasma apo(a) levels in postpubertal male YAC-apo(a) transgenic mice.
Another stimulus for these studies is the finding that high plasma levels of GH are associated with elevations in plasma concentrations of Lp(a) in humans. Acromegalics have increased plasma levels of Lp(a), and successful treatment of this condition results in a fall in the plasma level of Lp(a) that is proportional to the decrease in GH levels. 15, 16 Administration of GH to normal or GH-deficient humans results in a significant increase in plasma levels of apo(a) (for review see reference 17). The reason why GH therapy increases plasma levels of apo(a) in humans is not known. Many of the physiological effects of GH are mediated by insulin-like growth factor-1 (IGF-1), 18 but ironically, IGF-I administration to humans results in a decrease rather than increase in plasma levels of Lp(a). 19 -22 In this study, we have used a recently developed transgenic mouse line that expresses a 370 kb fragment containing the entire apo(a) gene as well as 40 kb of 5Ј and 200 kb of 3Ј sequence to examine the effect of GH and IGF-1 treatment on the expression of apo(a). 23 
Methods

Animals and Experimental Design
Mice (University of Texas Southwestern Medical Center, Dallas) expressing a 370-kb human DNA fragment containing the entire apo(a) gene, 40 kb of 5Ј-flanking and 200 kb of 3Ј-flanking sequence in a mixed C57Bl/6 and SJL background [YAC-apo(a) mice] were used in these experiments. 23 The mice were back-crossed into the C57Bl/6 strain, and at 1 month of age, venous blood was collected by retro-orbital puncture from the N 2 and N 3 generations. Plasma was subjected to immunoblot analysis, 7 and mice with immunodetectable apo(a) were entered into the study. All the mice in the study were heterozygous for the YAC-apo(a) transgene.
The transgenic mice were housed in a conventional, non-germfree animal facility with 12-hour dark/light cycles. The mice were weaned at 21 days and fed a cholate-free, standard mouse chow diet containing 6% animal fat and Ͻ0.04% cholesterol (Teklad, mouse/ rat diet 7002: Harlan Teklad) with free access to water. Surgical castration was performed in male and female mice at 10 weeks of age, and these mice were entered into the study 4 weeks after surgery.
Recombinant human growth hormone (rhGH) was a gift from Eli Lilly (Indianapolis, IN). The rhGH was diluted in 150 mmol/L NaCl and 10 mmol/L Tris, pH 7.4, and administered to 10-week-old mice by continuous infusion using an osmotic mini-pump, type 2001(Alza Corporation) implanted subcutaneously through a small incision below the scapula of the mouse. Control mice received vehicle alone. The mice receiving intermittent rhGH therapy received the same daily dose of GH administered directly into the peritoneal cavity in divided doses every 12 hours. The mice were weighed daily at 10
A total of Ϸ200 L of venous blood was obtained by retro-orbital puncture using heparinized capillary tubes (Microvette CB1000, Sarstedt) before initiation of rhGH treatment. At the indicated time intervals, the mice were fasted for 5 hours before administering sodium phenobarbital (Abbott Laboratories). The animals were exsanguinated by cannulating the left ventricle of the heart with an 18 gauge needle and slitting open the right atrium. The mice were perfused with 50 mL of phosphate buffered saline (pH 7.4), and the livers were collected and stored in liquid nitrogen.
Recombinant human insulin-like growth factor-I (rhIGF-1) was kindly provided by Genentech (South San Francisco, CA). The IGF-1 was diluted with 0.9% NaCl at a concentration of 8.4 g/L and administered to mice (100 g/d) by a continuous infusion (0.5 L/h) using a mini-osmotic pump (Alzert 2002).
Immunoblot Analysis of Apo(a)
Venous blood was collected in heparinized capillary tubes from the retro-orbital plexus before treatment and at the end of each experiment. Plasma was isolated by centrifugation at 5000g for 10 minutes, aliquoted, and stored at Ϫ80°C. A total of 0.3 L of plasma was subjected to immunoblot analysis using an anti-apo(a) monoclonal antibody (IgG-a5) or rabbit anti-rat apoAI antibody, 24 exactly as previously described. 25 Measurement of Plasma Apo(a), Growth Hormone, and IGF-I Plasma samples were stored at Ϫ80°C, and the apo(a) levels were quantified within 3 months of collection using a sandwich monoclonal antibody-based enzyme-linked immunosorbent assay. 26 Plasma concentrations of human GH were quantitated in duplicate using an hGH ELISA Kit (Boehringer Mannheim). The plasma levels of IGF-1 were measured at Genentech Laboratories using a radioimmunoassay as described. 27 The plasma was subjected to acid/ methanol precipitation to remove the IGF-1 from its binding proteins before measuring the total plasma IGF-1 level. The plasma levels of cholesterol and triglycerides were measured using Cholesterol/HP (Boehringer Mannheim) and Triglyceride (GPO-Trinder, Sigma) kits, respectively.
Northern Blot Analysis
Total cellular RNA was prepared from mouse tissues using RNA STAT-60 (TelTest B Inc) according to the instructions of manufacturer. Fifteen micrograms of RNA from each tissue was sizefractionated on a 1%(wt/vol) agarose, 0.6 mol/L formaldehyde gel and then transferred to nylon membranes (Hybond Nϩ, Amersham). A cDNA probe was generated from the apo(a) 8 K4-type 2 repeat using reverse transcriptase-PCR (Promega RT-PCR kit, Promega) and 2 oppositely-oriented oligonucleotides (5Ј-TGACAC-CACACTCGCATAGTCGGAC-3Ј and 5Ј-GATGACCAAGCT-TGGCAGGTTCTTCC-3Ј) 8 to amplify a 338 bp fragment from hepatic poly (A) ϩ mRNA isolated from our YAC-mice apo(a). The fragment was gel-purified and radiolabeled with [ 32 P]-dCTP (3000 Ci/mmol) using Megaprime DNA Labeling System (Amersham). The filters were allowed to hybridize with the 32 P-labeled probes (Ϸ1ϫ10 6 cpm/mL) for 2 hours at 65°C using Rapid-hyb buffer (Amersham).
A mouse IGF-I fragment containing the sequences of exon 3 was amplified using PCR, 2 oppositely-oriented oligonucleotides(5Ј-AGCCCACAGGCTATGGCTCC-3Ј and 5Ј-CTTCTGAGTCT-TGGGCATGTC-3Ј), and mouse genomic DNA. 28 A radiolabeled 1141-bp fragment from the rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA fragment 29 was included in the hybridization buffer. The filter was washed with 0.1% (wt/vol) SDS, 0.1xSSC (1xSSC: 150 mmol/L NaCl and 15 mmol/L NaCitrate) at 70°C for 30 minutes before being exposed to Reflection NEF 496 film (Dupont-NEN) at Ϫ80°C with an intensifying screen. A cDNA probe for mouse apoAI was obtained from Drs Jay Horton and Hitoshi Shimano (University of Texas Southwestern Medical Center, Dallas). 30 
Statistical Methods
The values are expressed as meansϮSD. Comparisons were made using a 2-tailed Student's t test.
Results
To examine the effect of GH on plasma levels of apo(a), we administered rhGH to mice expressing a human apo(a) gene in its own genomic context. We used mice containing a human genomic fragment that includes the entire apo(a) gene, 40 kb of 5Ј-and 200 kb of 3Ј-flanking sequence, respectively. In this article these mice are referred to as YAC-apo(a) transgenic mice. 23 Before puberty, the male and female mice have similar plasma levels of apo(a). 23 After puberty, the male YAC-apo(a) transgenic mice have a significantly lower mean plasma level of apo(a) than their female counterparts [1.2Ϯ0.91 (nϭ20) versus 8.14Ϯ2.6 mg/dL (nϭ20)].
To determine whether GH treatment increases plasma apo(a) levels in the YAC-apo(a) transgenic mice, postpubertal male mice (10 weeks old) were treated with a continuous infusion of either rhGH or vehicle alone for 7 days. The dosage of rhGH administered ranged from 0.625 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 (daily dose per animal:15 to 19 g) to 10 mg ⅐ kg Ϫ1 ⅐ d
Ϫ1
(daily dose: 250 to 300 g). The plasma rhGH levels were measured using an ELISA assay that detects human but not mouse GH ( Figure 1 ). A direct relationship was seen between the daily dosage of rhGH administered to the mice and the plasma level of hGH (Panel A). No hGH was detected in the plasma of the mice given vehicle alone. The levels of hGH ranged from 7.6 ng/mL in the mice treated with 0.625 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 to 40.2 ng/mL in the mice given 10 mg ⅐ kg Ϫ1 ⅐ d
. To confirm that the infused growth hormone was physiologically active, we monitored the body weights of the mice. A dose-dependent increase in weight was seen in association with rhGH treatment (Panel B). Animals receiving the highest daily dose of rhGH (10 mg ⅐ kg
) had a mean increase in body weight of Ϸ10%.
A significant dose-dependent increase in the plasma levels of apo(a) was seen in the rhGH treated mice ( Figure 1C ). The mean plasma levels of apo(a) increased 3.5-fold at the lowest dose (0.625 mg ⅐ kg Ϫ1 ⅐ d
) and 15-fold at the highest dose
). No significant change in plasma level of apo(a) was seen in the animals treated with buffer alone. Thus, administration of rhGH is associated with a significant increase in plasma apo(a) in post-pubertal male YAC-apo(a) transgenic mice.
The serum glucose, alanine transaminase, aspartate aminotransferase, bilirubin, and albumin, as well as the plasma cholesterol and plasma triglycerides, were measured on pooled samples from each group. No consistent changes or trends were observed in the serum levels of glucose, alanine transaminase, bilirubin, or albumin. The plasma levels of aspartate aminotransferase increased with rhGH treatment, although the effect was not dose-dependent. No significant change was seen in plasma cholesterol levels. The plasma Figure 1 . Dose-response effect of rhGH treatment on plasma human GH levels, body weight (percent change), and mean plasma level of apo(a) in 10-week-old male YAC-apo(a) male. Adult male mice (nϭ3) were treated for 7 days with a continuous infusion of rhGH at the indicated doses or vehicle alone (labeled 0) using a mini-osmotic pump. On day 7, venous blood was collected via retro-orbital puncture, and the plasma was isolated and stored at Ϫ80°C. A, After 1 week the plasma levels of hGH were measured in duplicate using an ELISA assay as described in the Methods. The mean plasma levels (ϮSD) of human GH in the mice are shown. B, The mice were weighed daily at 10 AM and the mean percent change in body weight (ϮSD) for each group over the 7-day duration of the experiment are given. C, The plasma apo(a) levels were measured on samples obtained at the end of the treatment period using an apo(a)-specific ELISA assay. 26 The plasma apo(a) levels represent means (ϮSD) from each group and are significantly different from placebo-treated animals. *PϽ0.05; **PϽ0.01; and ***PϽ0.0001. Venous blood was drawn by retro-orbital sinus puncture and collected into polypropylene vials or heparinized capillary tubes. The serum was allowed to incubate at 37°C for 1 hour and 300 L of serum from each animal was pooled together. Serum chemistries were measured in the clinical chemistry laboratory (University of Texas Southwestern Medical Center at Dallas, TX). The plasma cholesterol and triglyceride level was quantitated on pooled plasma stored at 4°C and measured within 1 week of sampling. ALT indicates alanine transaminase; AST, aspartate aminotransferase.
TABLE 1. Serum Chemistries and Plasma Lipid Levels in Pooled Samples From Adult YAC-Apo(a) Transgenic Male Mice (n‫)3؍‬ Treated With a Continuous Infusion of rhGH for 7 Days
triglyceride level increased by 28% at the highest dose of rhGH (Table 1) . To determine the distribution of cholesterol between the lipoprotein classes, the plasma samples were pooled and subjected to size-fractionation on a Superose 6 column. In rhGH treated animals, there tended to be a reduction in the cholesterol content of the HDL fraction associated with a slight shift to larger sized HDL particles. No significant changes were seen in the VLDL or LDL fraction (data not shown).
Immunoblot analysis of plasma apo(a) from representative postpubertal adult male mice is shown in Figure 2 . The animals that received vehicle alone had only a trace amount of immunodetectable apo(a) in their plasma. A dramatic increase in the amount of apo(a) was seen in the mice treated with rhGH. The effect of rhGH was not a generalized effect on all plasma proteins synthesized by the liver. No change was seen in the plasma levels of immunodetectable apoAI.
To determine whether rhGH treatment was associated with an increase in the amount of apo(a) mRNA, Northern blot analysis was performed using total RNA from multiple tissues of mice treated with the highest dose of rhGH. No apo(a) mRNA transcript was detected in the brain, heart, kidney, muscle, adipose tissue, spleen, testes, and ovary of the YAC-apo(a) transgenic mice (data not shown). Northern blot analysis of total hepatic mRNA using an apo(a)-specific probe revealed a single band of 7.5 kb in all the mice (including the mice treated with vehicle alone when the film was subjected to a longer exposure) ( Figure 3A) . The relative amount of apo(a) mRNA was 12-fold higher in the mice receiving the highest dose of rhGH (10 mg ⅐ kg Ϫ1 ⅐ d
Ϫ1
) than in the mice receiving vehicle alone. Although there were interindividual variations in the amount of apo(a) mRNA, the level correlated with the plasma levels of apo(a) in the 18 animals studied (R 2 ϭ0.93) ( Figure 3B ). No significant changes in the level of hepatic apoB-100 mRNA were observed with rhGH treatment (data not shown). Taken together, these data are consistent with the increase in plasma apo(a) levels associated with rhGH treatment being due to an effect of rhGH on the rate of apo(a) transcription or on the stability of the apo(a) mRNA in the liver.
To determine the time course of the increase in hepatic apo(a) mRNA and the plasma levels of apo(a), adult male mice were treated with 2.5 mg rhGH ⅐ kg Ϫ1 ⅐ d Ϫ1 for 1 to 7 days. A 1.7-fold increase in hepatic apo(a) mRNA levels was seen within the first 24 hours, and a further increase was observed over the ensuing 2 days (Figure 4, top panel) ; no change in apo(a) mRNA level was seen between days 3 and 7. Parallel changes were seen in the plasma levels of apo(a) (Figure 4, bottom panel) , which also reached a plateau by day 3. These results are consistent with the rhGH-associated increase in plasma apo(a) resulting from the effect of the hormone on the levels of hepatic apo(a) mRNA.
To determine whether rhGH has a similar apo(a)-elevating effect in female mice, we treated 3 females for 7 days with rhGH by continuous infusion at a dosage of 10 mg ⅐ kg Ϫ1 ⅐ d
( Table 2 ). The mean percent increase in body weight was Ϫ1.5% in the control group and 4.6% in rhGH-treated group. The percent change in plasma apo(a) level was determined by comparing the mean of the pretreatment values to the posttreatment levels. No significant change was seen in the mice treated with vehicle alone (nϭ3). In the female mice treated with high-dose rhGH, a 2-fold increase in plasma apo(a) was seen. Northern blot analysis of the hepatic mRNA from these mice showed a 1.5-fold increase in the mRNA level after rhGH treatment (data not shown). Thus rhGH had a more Figure 2 . Immunoblot analysis of plasma apo(a) from 10-weekold male YAC-apo(a) transgenic mice treated with a continuous infusion of rhGH for 7 days. Three mice in each group were treated with the indicated doses of rhGH, as described in the legend to Figure 1 . A total of 0.25 L of plasma from 2 mice of each group was subjected to reduction and size-fractionated on a 5% SDS-polyacrylamide gel, transferred to a nylon membrane, and immunoblotted using either an anti-human apo(a) monoclonal antibody (IgG-a5) (upper panel) conjugated to horseradish peroxidase or a rabbit anti-rat apoAI polyclonal antibody (lower panel). 45 The filters were developed using the ECL system (RPN 2106, Amersham Life Science) and exposed to film for 5 minutes at room temperature.
Figure 3.
A, Northern blot analysis of hepatic apo(a) mRNA from adult male YAC-apo(a) mice treated with rhGH by continuous infusion at the indicated daily doses for 7 days. After 7 days of treatment with rhGH, total RNA was isolated from the livers of the mice. A total of 15 g of RNA was subjected to Northern blot analysis using a 32 P-labeled 338 bp fragment from the K4-type 2 repeat of apo(a) and a 1141 fragment from rat GAPDH as probes. B, Relationship between plasma level of apo(a) and hepatic apo(a) mRNA. The amount of radioactivity in each band of the Northern blot was quantified using a BioImaging Analyzer with BAS100 BacBAS software (Fuji Medical System). The fold-increase in apo(a) mRNA relative to the control mice was calculated after loading differences were corrected by using the GAPDH signal as a control. Plasma levels of apo(a) were quantitated as described. 26 modest elevating effect on hepatic apo(a) mRNA and plasma levels of apo(a) in female YAC-apo(a) transgenic mice than their male counterparts.
Adult male (nϭ6) and female mice (nϭ6) were castrated to examine the effect of endogenous sex steroids on the apo(a)-elevating effect of rhGH. Recombinant hGH was given by continuous infusion at 2.5 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 for 4 days starting 1 month after castration. Castration has no significant effect on plasma levels of apo(a) in the female mice (Table 3) , which is similar to what was previously reported in the other YAC-apo(a) transgenic mouse line. 9 In noncastrated female mice, a 33% increase in plasma apo(a) was seen in the rhGH-treated mice. In the castrated females, treatment with rhGH resulted in a larger increase in plasma apo(a) levels (6.8Ϯ1.9 to 14.0Ϯ5.8 mg/dL) than was seen in the noncastrated mice. This suggests that estrogen may antagonize somewhat the apo(a)-elevating effect of rhGH in the mice, although more animals need to be studied to confirm this finding.
Castration was associated with a much more dramatic increase in plasma apo(a) levels in the male than female YAC-apo(a) transgenic mice. The plasma level of apo(a) increased 6-fold in the noncastrated male mice that were treated with 2.5 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 of rhGH by continuous infusion, which was similar to the results of our prior experiment (see Figure 1 ). In the castrated male mice, no significant increase in plasma levels of apo(a) was seen in association with rhGH treatment.
To determine whether the method of delivery of rhGH to the animals influenced the effect of the hormone on plasma levels of apo(a), we administered 2.5 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 of rhGH or vehicle alone via intraperitoneal injection every 12 hours for 4 days to adult male mice (nϭ3 in each group). Measurement of human GH at 1, 3, and 6 hours revealed that at 1 hour the level was between 250 to 400 ng/mL, and the level decreases to below the detectable range after 6 hours. No difference in plasma levels of apo(a) were seen between the control (1.36Ϯ1.04 mg/dL) and rhGH-treated groups (1.26Ϯ0.96 mg/dL) ( Table 4 ). When the treatment was extended for 6 days, a modest increase in the mean plasma apo(a) level (from 1.56Ϯ1.04 to 2.43Ϯ0.75 mg/dL) was seen (data not shown). In the same experiment, mice were treated with identical daily dose of rhGH but administered as a continuous infusion. These mice had plasma levels of human GH range from 12 to 26 ng/mL. As expected, there was a significant increase in plasma levels of apo(a). Thus the same daily dose of rhGH that caused an increase in plasma levels of apo(a) when given as a continuous infusion did not result in a significant elevation in the plasma level of apo(a) when administered as an intermittent injection despite observing an increase in body weight.
One of the effects of GH in the mouse is to increase the synthesis and secretion of IGF-1 by the liver. To determine whether the administration of rhGH was associated with an were treated with a continuous infusion of rhGH at 2.5 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 using an osmotic pump. Top panel, The livers were harvested at the indicated time intervals and Northern blot analysis was performed using total hepatic mRNA as described in Figure 3 . Bottom panel, Venous blood was obtained via retroorbital puncture after a 5-hour fast immediately before the mice were killed. The plasma was isolated and the levels of apo(a) determined as described in Figure 2 .
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increase in IGF-1 expression, we examined the level of hepatic IGF-1 mRNA and plasma levels of IGF-1 in the rhGH-treated adult male YAC-apo(a) transgenic mice ( Figure  5 ). Two mRNA transcripts of 0.8 and 7.5 kb are generated from the murine IGF-1 gene, 28 and both increased significantly (PϽ0.05) in response to administration of recombinant hGH treatment. A 2.2-fold increase in the level of the 7.5 kb transcript and a 2.7-fold elevation in the amount of the 0.8 kb transcript was seen at the highest dose. A radioimmunoassay assay that measures total IGF-1 was used to measure the plasma IGF-1 levels in these animals (Lyn Powell-Braxton, Genetech). The mean level of plasma IGF-1 in normal mice is 164.8Ϯ11.6 ng/mL. 31 The highest dose of GH was associated with only a 22% increase in the plasma level of IGF-1, which was not statistically significant. To determine whether the apo(a)-elevating effect of rhGH was mediated by IGF-1, 3-month-old castrated and noncastrated male and female YAC-apo(a) transgenic mice were treated with 100 g of IGF-1 by continuous infusion for 14 days. Plasma was obtained 7 and 14 days after initiation of treatment, and the apo(a) levels were measured ( Figure 6 ). In the noncastrated male YAC-apo(a) transgenic mice, no change was seen in the plasma levels of apo(a). In contrast, the mean plasma levels of apo(a) in the noncastrated female mice fell 2.5 fold (from 9.4Ϯ2.0 to 3.7Ϯ14 mg/dL) after IGF-1 treatment. No change in plasma apo(a) levels was seen in the animals administered vehicle alone. A decrease of similar magnitude was seen in the plasma levels of apo(a) after IGF-1 treatment (Ϸ60% decrease) in both the male and female castrated mice ( Figure 6A, panels C and D) . Thus, the apo(a) elevating effect of rhGH in these mice was not mediated by IGF-1.
Northern blot analysis was performed using total hepatic RNA, and the relative amounts of apo(a) mRNA were determined using a phosphoimager. The relative amounts of apo(a) mRNA tended to correlate with the levels of plasma apo(a) ( Figure 6B ). These results are consistent with the effects of IGF-1 on the plasma levels of apo(a) being due to changes in the level of transcription of the apo(a) gene or stabilization of the apo(a) mRNA.
Discussion
We have shown that administration of rhGH to mice expressing a human apo(a) transgene under the control of its own regulatory sequences is associated with a significant increase in the hepatic content of apo(a) mRNA and levels of plasma apo(a). The apo(a)-elevating effect of rhGH was most pronounced in the postpubertal male mice; a significant increase in the plasma levels of apo(a) occurred within 24 hours of initiating rhGH treatment, and the levels reached a maximum at 3 days. To determine whether the effect of rhGH Figure 5 . Dose-response effect of administration of rhGH on hepatic levels of IGF-1 mRNA in adult male YAC-apo(a) transgenic mice. Adult male YAC-apo(a) transgenic mice were treated with rhGH by continuously infusion exactly as described in the legend to Figure 1 . After 7 days of treatment, the animals were killed, and the livers were obtained. Northern blot analysis was performed as described in Figure 1 , except that the filter was allowed to hybridize with an IGF-1-specific probe. The 7.5 and 0.8 kb signals represent different splice products of the IGF-1 gene. 28 The relative intensities of the 2 IGF-1 bands were compared with the mice that received vehicle alone, as described in Figure 1 . The plasma IGF-1 levels were measured at Genentech using an RIA assay. 31 Figure 6 . Effect of rhIGF-1 on plasma apo(a) levels in male and female castrated and noncastrated mice (A) and on the levels of hepatic apo(a) mRNA. The female and male mice were castrated at 8 and 10 weeks of age, respectively. One month after castration the mice were treated with a continuous infusion of rhIGF-1 (100 g/d for 14 days) or normal saline using a mini-osmotic pump. Venous blood was obtained by retro-orbital puncture 5 days before the initiation of rhGH treatment and 7 and 14 days after day 0. Plasma levels of apo(a) from each group of mice were measured using a sandwich ELISA assay. 26 In the castrated mice, blood was also obtained the day before castration and 3 weeks after castration. Mean plasma levels of apo(a) (Ϯ) SD are shown. B, Livers were collected at the end of the experiment and total hepatic RNA was made. Northern blot analysis of apo(a) and GAPDH was performed and the relative amounts of apo(a) mRNA were compared after the signal intensities were quantitated as described in Figure 3 . Mean (Ϯ)SD of the relative intensities of the apo(a) mRNA signal are shown.
on plasma apo(a) levels was mediated by IGF-1, IGF-1 was administered to the YAC-apo(a) mice. IGF-1 treatment resulted in an Ϸ50% fall in plasma apo(a) levels in the transgenic mice. Therefore, the increase in plasma apo(a) associated with GH treatment is not due to its stimulatory effect on IGF-1. The directional effects of rhGH and IGF-I on the plasma levels of apo(a) in these animals simulate those seen in humans, and thus the YAC-apo(a) transgenic mice provide an excellent animal model in which to study the regulation of apo(a) expression by these agents.
Two YAC-apo(a) transgenic mice lines have been developed, and both demonstrate a sexually dimorphic pattern of apo(a) expression. 8, 23 Prepubertal male and female YAC apo(a) transgenic mice have similar plasma levels of apo(a) until puberty and then the levels fall dramatically in the males. 8, 23 The peripubertal fall in plasma apo(a) in the male YAC-apo(a) transgenic mice has been presumed to be due solely to the effect of testosterone because castration results in an increase in plasma apo(a) levels and administration of 5␣-dihydrotestosterone to the castrate male lowers plasma levels to the post-pubertal range. 8 An alterative explanation for these observations is that some of the effect of testosterone is indirect and due to the male-specific pattern of secretion of GH.
Adult male and female rodents have similar mean plasma levels of GH, but the sex steroid profile determines whether the GH is secreted intermittently in bursts (testosterone) or more continuously (estrogen). 11, 32 Interpulse intervals of at least 2 hours duration are required to achieve a male pattern of hepatic gene expression. 14 In male rodents, the male pulsatile pattern of GH secretions activates a number of members of the STAT transcription factor family (including STAT5), which have been implicated as mediating the GH-associated male-specific pattern expression of hepatic genes. 33 The male pattern of GH secretion may inhibit expression of the apo(a) gene in the postpubertal YAC-apo(a) transgenic mice. Consistent with this scenario is our observation that administration of a GH as a continuous infusion to postpubertal male mice resulted in an increase in plasma apo(a) to levels that are similar to those seen in females. Males that received intermittent administration of the same total daily dose of rhGH had no significant increase in their plasma levels of apo(a) ( Table 4 ). Thus it is not just the amount of rhGH administered but also the pattern of its delivery that affects plasma levels of apo(a).
The elevating response of plasma apo(a) levels to a continuous infusion of rhGH in the male transgenic mice is similar to what has previously been observed for another murine hepatic gene, the prolactin receptor. Hepatic prolactin receptor mRNA levels are much lower in male than female mice, but administration of GH by continuous infusion to male mice increases the level of the hepatic prolactin receptor into the "female" range. The same dose of GH, if administered as an intermittent infusion, has no effect on prolactin hormone receptor mRNA levels. 34 Humans differ from mice in that the pattern of GH secretion is not as dramatically different between the sexes, and there is no sexually dimorphic pattern of hepatic gene expression. Nor is there a significant difference between men and women in plasma levels of Lp(a). However, plasma levels of Lp(a) in humans are significantly affected by the circulating levels of GH (for review, see reference 35). Acromegalics have elevated plasma Lp(a) levels, and successful treatment of this disorder is associated with a decrease in plasma apo(a) levels proportional to the reduction in GH. 16, 15, 36 GH administration to adult individuals with GH deficiency result in a 30% to 200% increase in plasma Lp(a) levels. 32, 37 A significant increase in plasma apo(a) level also occurs when GH is given to normal adults. 38 Many of the biological effects of GH are mediated via IGF-1, but that is not true for the apo(a)-elevating effect of this hormone in mice (or men). Although recombinant hGH treatment was associated with detectable increase in hepatic IGF-1 mRNA levels, only a modest increase in the plasma levels of IGF-1 was seen in the YAC-apo(a) transgenic mice; it may be that mice develop tolerance to effects of the rhGH as has been proposed previously. 28 IGF-1 treatment of YACapo(a) transgenic mice resulted in a significant fall in plasma apo(a) levels, which mirrors the direction of effect of IGF-1 on plasma levels of Lp(a) in humans. Recombinant IGF-1 (80
) administration to adult men for 1 week results in a Ϸ10% reduction in plasma apo(a) levels. 19 More prolonged treatment of Laron dwarfs (who are resistant to the effects of GH so have high plasma levels of GH and low levels of IGF-1 in their plasma) results in a much more pronounced (66%) reduction in plasma levels of Lp(a), 21 which may be due to the lower initial plasma levels of IGF-1 in these individuals. IGF-1 is also effective at lowering plasma Lp(a) levels in GH-deficient subjects, who also have low IGF-1 levels. 20 Thus the fall in plasma Lp(a) levels with IGF-1 treatment must be independent of its it effect on reducing the plasma levels of GH.
Our finding that oophorectomy was not associated with any increase in the plasma level of Lp(a) is similar to what was previously reported for the other strain of YAC-apo(a) transgenic mice. 9 In the mouse, plasma GH levels are not significantly affected by oophorectomy, which is in contrast to the situation in humans. 39 Postmenopausal women tend to have higher plasma levels of Lp(a), 40 and administration of oral estrogen to humans is associated with a fall in IGF-1, increase in GH, 41 and reduction in plasma apo(a) levels. 42 These observations taken together make it unlikely that the reduction in plasma Lp(a) associated with estrogen therapy in humans is due to the effects of the hormone on the GH/IGF-1 axis.
Based on the results of our studies, we would predict that if the YAC-apo(a) transgenic mice were crossed with mice expressing a GH transgene, 43 the resultant mice that express both transgenes would have high plasma levels of apo(a). It would be interesting to cross the YAC-apo(a) transgenic mice with mice in which the STAT5b gene has been inactivated (Stat5b Ϫ/Ϫ ) because STAT5b has been implicated as being the transcription factor that mediates the effect of a pulsatile GH pattern on hepatic gene expression in rodents. 33, 44 The male Stat5b Ϫ/Ϫ mice have higher hepatic levels of many of the mRNA species that are low in wild-type males, including the CYP15␣/2A4, prolactin receptor, and CYP6B/3A mRNAs. The levels of these mRNA transcripts in the male Stat5b Ϫ/Ϫ mice more closely resemble the levels seen in wild-type females. 44 It would be expected that the expression levels of apo(a) would be higher in the male mice YAC-apo(a) 
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Recently a YAC-apo(a) transgenic rabbit was developed using the same construct used to generate one of the mice lines. 45 Interestingly, the plasma levels of apo(a) do not fall at puberty in the male YAC-apo(a) transgenic rabbits. Unlike rats and mice, rabbits do not have sexually differentiated livers, which again is consistent with the puberty-associated reduction in plasma apo(a) levels in the YAC-apo(a) transgenic mice being mediated by the rodent-and male-specific pattern of GH secretion rather than solely as a direct effect of testosterone.
Finally, the results of these studies demonstrate that changes in apo(a) gene transcription [or apo(a) mRNA stability] have significant effects on the plasma level of apo(a). These mice provide a much needed animal model that can be used to define the sequences that regulate the expression of the apo(a) gene. The mice can also be used to examine the effects of potential therapeutic agents on apo(a) gene transcription, mRNA translation, and the plasma level of apo(a).
